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It is generally accepted that, in actual clinical practice, the concentration of cyclosporine in
blood is the principal determinant of the dosage to be prescribed for a given patient. However,
many physicians, in describing immunosuppression policies, still refer to the dose of
cyclosporine prescribed after transplantation. The present analysis was undertaken to
determine the degree of correlation between the dose and level of cyclosporine in stable liver
transplant recipients.
PATIENTS AND METHODS
The records of all adult patients who underwent orthotopic liver transplantation at the
Presbyterian-University Hospital, Pittsburgh, between January and October 1987 were
evaluated.
Immunosuppression Protocol
The techniques for orthotopic liver transplantation and immunosuppressive protocols utilized
in these cases have been described in detail previously.1,2 In particular, all patients were treated
with a combination of cyclosporine and steroids. Cyclosporine (17.5 mg/kg) was administered
orally preoperatively. During the operation Medrol 1g and cyclosporine (2 mg/kg) were given
intravenously at the time of revascularization of the graft. Postoperatively, the patients received
Medrol 200 mg. which was reduced by 40 mg daily until a maintenance dose of 20 mg daily
was achieved, and cyclosporine 6 mg/kg intravenously in 3 divided doses. Oral cyclosporine
(20 mg/kg) was introduced as soon as the patients had stabilized after the transplant procedure
and resumed an oral diet. The dose of cyclosporine was adjusted to maintain a 12-hour
cyclosporine whole blood trough level of approximately 1000 ng/mL.
Rejection episodes, in the presence of adequate cyclosporine levels, were treated with a
solumedrol bolus. A re-cycle of the Medrol was used in the patients who failed to respond to
the steroid bolus. Steroid resistant rejection episodes were treated with the monoclonal
antibody OKT3.
Cyclosporine levels were determined on whole blood utilizing a radioimmunoassay kit
obtained from Sandoz.
The whole blood cyclosporine level achieved and the dose of cyclosporine used for each patient
at the time of the first outpatient visit were recorded. This time-point for analysis was chosen
because patients are discharged from hospital only if graft function and whole blood
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cyclosporine levels are stable. Typically patients are discharged three to eight weeks after
transplantation.
RESULTS
Thirty-one male and 44 female consecutive adult liver transplant recipients who survived for
greater than 3 months with stable allograft function were included in the study. The mean age
of the patients was 43.36 ± 1.33 years (mean ± SEM) and the ages ranged from 21 to 70 years.
The doses of cyclosporine used in these patients, as shown in Fig 1, ranged from 6 to 57 mg/
kg/day and the median dose was 15 mg/kg/day. Thirteen transplant recipients (17.3%) received
doses less than 12 mg/kg/day while 11 patients (14.7%) required doses greater than 22 mg/kg/
day.
The concentrations of cyclosporine in the blood in these stable allograft recipients are shown
in Fig 2. The median cyclosporine level was 1025 ng/mL with a range of 180 to 1925 ng/mL.
The cyclosporine level in one patient was only 180 ng/mL. However, despite this inadequate
cyclosporine level. this patient had normal bilirubin and transaminase levels. The remaining
74 liver recipients had cyclosporine levels greater than 500 ng/mL. Cyclosporine levels greater
than 1600 ng/mL were found in seven patients (9.3%).
The ideal cyclosporine level in liver transplant recipients with normal hepatic function and
without any evidence of cyclosporine toxicity, in our institution, should be between 700 and
1300 ng/mL. In this study 52 patients (69.3%) had cyclosporine levels within this range (Fig
3). The median dose of cyclosporine required to maintain ideal levels was 13 mg/kg/day with
a range of 6 to 57 mg/kg/day. This dose of cyclosporine required to maintain ideal levels was
less than 10 mg/kg/day in nine patients (17.3%) and was greater than 23 mg/kg/day in 11
patients.
DISCUSSION
Descriptions of the immunosuppression protocols used after organ transplantation typically
refer to the dose of cyclosporine (on a per weight basis) given to patients. In actual clinical
practice, however, the amount of cyclosporine given to patients is determined principally by
the level of the drug in the blood. This analysis of the amount of cyclosporine administered to
and the concentration of cyclosporine achieved in whole blood in 75 liver allograft recipients
revealed that the majority of patients had levels of cyclosporine within the standard or
universally accepted “therapeutic” range. A few patients with stable graft function had levels
which were outside the therapeutic range. The dose of cyclosporine required to maintain these
levels varied widely in these patients.
Furthermore, this study demonstrated that the trough concentration of cyclosporine achieved
in blood did not correlate with the dose of cyclosporine ad ministered to stable transplant
recipients. This study emphasizes the fact that immunosuppression protocols must include
measurements of the level of cyclosporine achieved in blood and not simply the dose of the
drug administered.
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Fig 1.
Dose of cyclosporine (mg/kg/day) used by the liver transplant recipients studied.
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Fig 2.
Concentration of cycyclosporinen in whole blood (ng/mL) in liver allograft recipients.
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Fig 3.
Dose of cyclosporine (mg/kg/day) required to achieve a cyclosporine level of 700-1300 ng/
mL in liver transplant recipients.
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